Advaxis, Inc.'s HER2 Immunotherapy Candidate Receives Orphan Drug Designation For Treatment Of Osteosarcoma
5/27/2014 9:04:14 AM
PRINCETON, N.J., May 27, 2014 (GLOBE NEWSWIRE) -- Advaxis, Inc., (Nasdaq:ADXS), a leader in developing cancer immunotherapies, announced that it has been granted Orphan Drug Designation (ODD) from the U.S. Food and Drug Administration (FDA) Office of Orphan Products Development (OOPD) for ADXS-cHER2 for the treatment of osteosarcoma.
Help employers find you! Check out all the jobs and post your resume.
comments powered by